Stockreport

A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value [Seeking Alpha]

Skye Bioscience, Inc.  (SKYE) 
PDF This presents potential value opportunities in a market projected to grow to $105 billion by 2035. Skye Bioscience's nimacimab, in Phase 2a trials, shows promise with [Read more]